EUVIMEDEUVIMED entdecken
Crossref

Pharmacogenomic Profiling of Voriconazole Enables Predicting Its Toxicity in Pediatric Leukemia and Hematopoietic Stem Cell Transplant Recipients—A Prospective Study From North India

Ankita Chakraborty iD, Manas Kalra iD, Renu Saxena, Hans Raj, Seema Bhargava, Anjali Manocha, Anupam Sachdeva

The Journal of Clinical Pharmacology · 2026-05 · 66 (5)

DOI: 10.1002/jcph.70198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 08.05.2026. Verfasst von Ankita Chakraborty und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology-Oncology and BMT unit, Sir Ganga Ram Hospital, New Delhi, India. Hauptthemen laut MEDLINE: Voriconazole, Cytochrome P-450 CYP2C19, Hematopoietic Stem Cell Transplantation, Antifungal Agents. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Voriconazole has variable pharmacokinetics, significant interactions, and a narrow therapeutic window, requiring drug monitoring. This study evaluated CYP2C19 genotype and voriconazole levels in North Indian children, a population with limited pharmacogenomic data. It is a prospective single‐center study (August 2023‐January 2025) in children with leukemia/HSCT. Voriconazole levels were measured using the ARK assay; CYP2C19 genotyping was done by PCR–Sanger, with phenotypes assigned per CPIC guidelines. A total of 102 patients (mean age 6.56 ± 4.22 years; M:F 1.9:1) were enrolled, with B‐ALL being most common diagnosis (77.5%). Voriconazole levels showed marked variability, with only 52.9% in the therapeutic range (1‐5.5 µg/mL). Intermediate (33.3%) and normal (30.4%) metabolizers predominated. CYP2C19 genotype correlated significantly with levels ( P < 0.001): poor metabolizers (*2/*2) had the highest concentrations (8.73 ± 2.22), normal (*1/*1) and intermediate were in the therapeutic range (∼3.2 µg/mL), and rapid metabolizera had subtherapeutic levels (1.65 ± 3.21). Median levels in *1/*2 and *2/*2 were 1.9‐ and 5.3‐fold higher than in rapid metabolizers. Hepatotoxicity, defined as ALT/AST ≥5× ULN or ≥3× ULN with symptoms or hyperbilirubinemia, occurred in 28.4% and was significantly associated with supratherapeutic levels; toxicity correlated more strongly with drug exposure than with CYP2C19 genotype alone. Multivariate analysis identified genotype ( P < 0.001) and dose ( P = 0.0021) as key determinants of drug levels, whereas age, gender, and weight were not significant. This prospective study shows a strong link between CYP2C19 genotype and voriconazole exposure in children, supporting genotype‐guided dosing with therapeutic drug monitoring and highlighting the need for ancestry‐informed precision dosing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleCytochrome P-450 CYP2C19Hematopoietic Stem Cell TransplantationAntifungal AgentsLeukemiaHumansFemaleChildMaleProspective StudiesIndiaChild, PreschoolAdolescentGenotypeDrug MonitoringInfantPharmacogenetics

Stichwörter der Autor:innen

CYP2C19 genotypingantifungalmetabolizertherapeutic drug monitoringvoriconazole

Substanzen

VoriconazoleCytochrome P-450 CYP2C19Antifungal AgentsCYP2C19 protein, human

Autor:innen und Institutionen

  • Pediatric Hematology-Oncology and BMT unit, Sir Ganga Ram Hospital, New Delhi, India.
  • Molecular Genetics Laboratory, Institute of Medical Genetics and Genomics, Sir Ganga Ram Hospital, New Delhi, India.
  • Department of Biochemistry, Sir Ganga Ram Hospital, New Delhi, India.

ORCID-Profile: Ankita Chakraborty, Manas Kalra

Zitieren

APA

Chakraborty, A., Kalra, M., Saxena, R., Raj, H., Bhargava, S., Manocha, A., & Sachdeva, A. (2026). Pharmacogenomic Profiling of Voriconazole Enables Predicting Its Toxicity in Pediatric Leukemia and Hematopoietic Stem Cell Transplant Recipients—A Prospective Study From North India. The Journal of Clinical Pharmacology, 66(5). https://doi.org/10.1002/jcph.70198

Vancouver

Chakraborty A, Kalra M, Saxena R, Raj H, Bhargava S, Manocha A, et al. Pharmacogenomic Profiling of Voriconazole Enables Predicting Its Toxicity in Pediatric Leukemia and Hematopoietic Stem Cell Transplant Recipients—A Prospective Study From North India. The Journal of Clinical Pharmacology. 2026;66(5). doi:10.1002/jcph.70198

BibTeX
@article{Chakraborty2026,
  author = {Chakraborty, Ankita and Kalra, Manas and Saxena, Renu and Raj, Hans and Bhargava, Seema and Manocha, Anjali and Sachdeva, Anupam},
  title = {Pharmacogenomic Profiling of Voriconazole Enables Predicting Its Toxicity in Pediatric Leukemia and Hematopoietic Stem Cell Transplant Recipients—A Prospective Study From North India},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {5},
  doi = {10.1002/jcph.70198}
}
Kostenlos starten →